| Brand Name | Pharmafleet |
|---|---|
| Industry | Healthcare & Pharmaceutical Retail |
| Business Category | Pharmacy / Healthcare Services Outlet |
| Founded Year | 2021 |
| Franchise Started | 2023 |
| Total Franchise Outlets | 10–20 |
| Estimated Investment | INR 50 Lakh–1 Cr |
| Franchise Fee | INR 5,00,000 covering brand licensing and onboarding support |
| Royalty Fee | 5% of revenue, standard for ongoing operational and brand support |
| Space Requirement | 1,200–2,000 sq. ft. |
| Staff Requirement | Retail and operations staff for pharmacy, diagnostic, and delivery services |
| Expected Payback Period | 5–10 Years |
Pharmafleet operates as a consumer healthcare platform delivering prescription medicines, OTC products, veterinary medicines, and diagnostic services. It serves end-consumers seeking timely, reliable, and affordable healthcare. The brand falls under the broader pharmacy and healthcare franchise category, combining physical retail with digital ordering and home delivery capabilities.
Pharmafleet functions as a pharmacy and healthcare service outlet integrated with a digital platform. Customers interact through in-store visits or the mobile app for product selection and order placement. Operations include inventory management, dispensing medicines, handling diagnostic service requests, and coordinating home delivery. Revenue is generated via retail sales, service fees, and transaction-based delivery charges.
| Prescription Medicines | Allopathic, Ayurvedic, Homeopathic |
|---|---|
| Over-the-Counter (OTC) Products | Supplements, personal care items, FMCG healthcare goods |
| Veterinary Medicines | Health products for pets and animals |
| Diagnostic Test Services | Home-based diagnostic and preventive health tests |
| Digital Services | Online ordering, mobile app integration, and home delivery |
Franchise partners operate outlets under the Pharmafleet brand license. Responsibilities include managing retail operations, inventory, customer service, diagnostic service coordination, and digital platform support. The franchisor provides operational protocols, training, technology access, and ongoing support to ensure service consistency, quality, and compliance across all outlets.
| Estimated Investment | INR 50 Lakh–1 Cr for outlet setup, inventory, and operational readiness |
|---|---|
| Franchise Fee | INR 5,00,000 for brand licensing, onboarding, and training |
| Setup Costs | Store interiors, shelving, diagnostic equipment, IT infrastructure, and initial stock |
| Royalty Payments | 5% of revenue for continued support, technology maintenance, and brand compliance |
The investment covers infrastructure, technology integration, and staffing for a large-scale pharmacy and healthcare outlet.
| Space Requirement | 1,200–2,000 sq. ft. for retail, diagnostic, and service operations |
|---|---|
| Location Preference | Urban or semi-urban areas with high footfall and accessibility |
| Equipment Needs | Shelving, POS systems, refrigeration, diagnostic equipment, IT systems |
| Staffing Considerations | Pharmacists, service staff, delivery personnel, and administrative support |
| Operational Training | Pharmacy management, diagnostic service handling, and customer service |
|---|---|
| Launch Assistance | Store setup, inventory planning, and technology deployment |
| Marketing Support | Brand campaigns, local promotions, and digital marketing guidance |
| Supply Chain Systems | Access to pharmaceutical suppliers, diagnostic partners, and delivery coordination |
| Ongoing Guidance | Operational monitoring, technology support, and process optimization |
Revenue is generated through pharmacy product sales, diagnostic service fees, and home delivery charges. Key drivers include:
| Pricing Model | Competitive and service-inclusive pricing |
|---|---|
| Demand Drivers | Growing need for accessible healthcare and home delivery services |
| Repeat Customer Potential | Encouraged through subscription-based deliveries and loyalty programs |
| Operational Costs | Staff salaries, inventory procurement, delivery logistics, and utilities |
Expected payback period is 5–10 years based on outlet scale and service adoption.
Pharmafleet was founded in 2021 and began franchising in 2023. The brand currently operates 10–20 outlets, initially focused on Bangalore with plans for PAN India expansion. Growth strategy includes integrating digital services, expanding diagnostic capabilities, and building a nationwide network of pharmacy and healthcare service outlets.
Pharmafleet combines a physical pharmacy outlet with a digital platform, providing home-delivered healthcare products and diagnostic services. Its operational distinctiveness lies in omnichannel integration, diverse product offerings, and reliable home healthcare solutions.
Investors may also consider:
These franchises operate within the pharmacy and healthcare sector, offering comparable physical and digital service models.
Estimated investment ranges from INR 50 Lakh to 1 Cr, including store setup, initial inventory, technology integration, and operational readiness. Franchise fees are INR 5,00,000, with a 5% royalty on revenue for ongoing support and platform maintenance.
Franchise partners manage retail sales, diagnostic services, and home delivery operations. The franchisor provides training, operational guidelines, technology access, and ongoing support to maintain consistent service quality across outlets.
Outlets require 1,200–2,000 sq. ft., accommodating pharmacy retail, diagnostic service areas, staff, and delivery coordination facilities.
The expected payback period is 5–10 years, depending on service adoption, location, and operational efficiency.
Investors contact the franchisor to submit an application, evaluate site feasibility, and receive operational and technology training before launching the outlet. ## 13. Similar Franchise Opportunities
Disclaimer: All scores, rankings, and estimates on ForeFind are independently produced editorial assessments using publicly available data and validated brand-submitted information. They are not verified facts, financial advice, or investment recommendations. Full Disclaimer.